|
ES2210306T3
(es)
*
|
1994-07-20 |
2004-07-01 |
The General Hospital Corporation |
Sistemas de trampa para interacciones, para detectar interacciones de proteinas.
|
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
EP0830459B1
(de)
*
|
1995-04-11 |
2007-01-24 |
The General Hospital Corporation |
Reverse "two-hybrid"-systeme
|
|
EP1241265A3
(de)
*
|
1996-04-26 |
2004-02-18 |
Massachusetts Institute Of Technology |
Screening-Verfahren für kleine Liganden
|
|
CA2252886C
(en)
*
|
1996-04-26 |
2008-02-12 |
Massachusetts Institute Of Technology |
Three-hybrid screening assay
|
|
US5776689A
(en)
*
|
1996-07-19 |
1998-07-07 |
The Regents Of The University Of California |
Protein recruitment system
|
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
|
US5846722A
(en)
*
|
1996-10-16 |
1998-12-08 |
Terrapin Technologies, Inc. |
System to detect small molecule/peptide interaction
|
|
US6365347B1
(en)
*
|
1997-04-11 |
2002-04-02 |
The Regents Of The University Of California |
Method for identifying disruptors of biological pathways using genetic selection
|
|
EP1040201A4
(de)
*
|
1997-11-28 |
2001-11-21 |
Invitrogen Corp |
Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren
|
|
EP1035207A1
(de)
*
|
1999-03-09 |
2000-09-13 |
MultiGene Biotech GmbH |
cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
|
|
EP1171595A1
(de)
|
1999-04-12 |
2002-01-16 |
Agensys, Inc. |
13-transmembrane protein welches in prostatakrebs exprimiert wird
|
|
EP1792989A1
(de)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
CA2377573A1
(en)
*
|
1999-06-26 |
2001-01-04 |
Joelle Nina Pelletier |
An in vivo library-versus-library selection of optimized protein-protein interactions
|
|
EP1200590B1
(de)
|
1999-08-12 |
2009-01-07 |
Agensys, Inc. |
C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
|
|
CA2385032C
(en)
|
1999-10-05 |
2013-12-10 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
|
US6893818B1
(en)
*
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
|
US20030211495A1
(en)
*
|
2000-03-08 |
2003-11-13 |
Richard Hopkins |
Reverse n-hybrid screening method
|
|
DE60138465D1
(de)
|
2000-07-12 |
2009-06-04 |
Agensys Inc |
Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
|
|
EP2022797A3
(de)
|
2000-08-28 |
2011-11-09 |
Agensys, Inc. |
Nukleinsäure und entsprechendes Protein mit der Bezeichnung 85P1B3 für die Behandlung und den Nachweis von Krebs
|
|
WO2002022685A2
(en)
*
|
2000-09-11 |
2002-03-21 |
Kufe Donald W |
Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
|
|
WO2002026932A2
(en)
|
2000-09-26 |
2002-04-04 |
Duke University |
Rna aptamers and methods for identifying the same
|
|
WO2002058450A2
(en)
*
|
2000-12-22 |
2002-08-01 |
Dana-Faber Cancer Institute, Inc. |
Regulation of cell growth by muc1
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
ATE497603T1
(de)
|
2001-03-02 |
2011-02-15 |
Gpc Biotech Ag |
Drei-hybrid-assaysystem
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
EP1573024A4
(de)
|
2001-04-10 |
2007-08-29 |
Agensys Inc |
Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
|
|
PT2070939E
(pt)
*
|
2001-05-25 |
2014-06-09 |
Univ Duke |
Moduladores de agentes farmacológicos
|
|
WO2003022995A2
(en)
|
2001-09-06 |
2003-03-20 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
|
|
US20040049024A1
(en)
*
|
2001-12-07 |
2004-03-11 |
Geoff Clark |
Compositions and methods related to the minn1 tumor suppressor gene and protein
|
|
US20040086945A1
(en)
*
|
2002-06-03 |
2004-05-06 |
The Procter & Gamble Company |
Hairless protein-interacting partner complexes and methods thereto
|
|
CA2542171C
(en)
*
|
2002-06-26 |
2015-12-15 |
Abbott Gmbh & Co. Kg |
Modulators and modulation of the interaction between rgm and neogenin
|
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
US20060099713A1
(en)
*
|
2002-10-01 |
2006-05-11 |
Buck Institute |
Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
|
|
CA2860151A1
(en)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
|
US20080090770A1
(en)
*
|
2003-04-11 |
2008-04-17 |
Belmares Michael P |
Modulation of Muc1 Mediated Signal Transduction
|
|
AU2004263823B2
(en)
|
2003-05-30 |
2008-09-18 |
Agensys, Inc. |
Prostate stem cell antigen (PSCA) variants and subsequences thereof
|
|
GB0315248D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Hoffmann La Roche |
HCV regulated protein expression
|
|
WO2005042573A1
(en)
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
|
EP1533619B1
(de)
|
2003-11-20 |
2009-04-29 |
F. Hoffmann-Roche AG |
Spezifische Marker für Stoffwechselssyndrome
|
|
EP1718367A1
(de)
*
|
2004-02-23 |
2006-11-08 |
Genzyme Corporation |
Muc1-antagonisten-verstärkung von durch todes-rezeptor-ligand ausgelöster apoptose
|
|
CN1980947B
(zh)
*
|
2004-04-22 |
2013-01-30 |
雷加多生物科学公司 |
改良的凝血因子调节物
|
|
RU2381234C2
(ru)
|
2004-05-28 |
2010-02-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками psca
|
|
US8034553B2
(en)
|
2004-06-24 |
2011-10-11 |
Kimberly-Clark Worldwide, Inc. |
Biomarkers for wound healing
|
|
EP3300739A3
(de)
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
WO2008025564A2
(en)
|
2006-08-31 |
2008-03-06 |
Nexigen Gmbh |
Methods for detecting protein-peptide interactions
|
|
EP1927364A1
(de)
*
|
2006-12-01 |
2008-06-04 |
Ecole Normale Superieure De Lyon |
Polypetitde mit modulatorischer Wirkung auf Zellen
|
|
WO2008097844A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Dana -Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
|
|
WO2008097840A2
(en)
|
2007-02-02 |
2008-08-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
|
|
EP2034020A1
(de)
*
|
2007-08-30 |
2009-03-11 |
Procomcure Biotech GmbH |
Verfahren zur Herstellung eines modifizierten Peptids
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2101173A1
(de)
*
|
2008-03-14 |
2009-09-16 |
Vivalis |
In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
|
|
US20110064202A1
(en)
*
|
2008-05-15 |
2011-03-17 |
Koninklijke Philips Electronics N.V. |
Method and system for generating an x-ray beam
|
|
JP2013507950A
(ja)
|
2009-10-22 |
2013-03-07 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク |
グアニン交換因子インヒビター及び抗癌剤としてのその使用
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
JP6743022B2
(ja)
|
2014-12-24 |
2020-08-19 |
ネクシミューン インコーポレイテッド |
免疫療法のためのナノ粒子組成物及び方法
|
|
EP3371311B1
(de)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bifunktionale chimäre proteine und verwendungen davon
|
|
EP3377080B1
(de)
|
2015-11-19 |
2024-02-14 |
Asclepix Therapeutics, LLC |
Peptide mit anti-angiogenen, anti-lymphangiogenen und anti-ödematösen eigenschaften und nanopartikelformulierungen
|
|
CN109071632B
(zh)
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
EP3455245A2
(de)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutisches targeting von nichtzellulären strukturen
|
|
WO2018067646A1
(en)
|
2016-10-04 |
2018-04-12 |
Asclepix Therapeutics, Llc |
Compounds and methods for activating tie2 signaling
|
|
CN110114368B
(zh)
|
2016-10-24 |
2024-08-02 |
奥睿尼斯生物科学私人有限公司 |
靶向突变干扰素-γ及其用途
|
|
EP3576765B1
(de)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Zielgerichtetes manipuliertes interferon und verwendungen davon
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
US11674959B2
(en)
|
2017-08-03 |
2023-06-13 |
The Johns Hopkins University |
Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
|
|
WO2019075056A1
(en)
|
2017-10-10 |
2019-04-18 |
The Johns Hopkins University |
BIODEGRADABLE BIOMIMETIC PARTICLES
|
|
GB2584211B
(en)
*
|
2017-11-16 |
2023-05-24 |
Synthex Inc |
Selective modulation of protein-protein interactions
|
|
US12655186B2
(en)
|
2018-01-26 |
2026-06-16 |
Orionis Biosciences, Inc. |
Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
EP3890773A4
(de)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
Modulation von dendritischen zelllinien
|
|
CN119708241A
(zh)
|
2019-02-15 |
2025-03-28 |
因特格尔莫来库乐有限公司 |
密封蛋白6抗体及其用途
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
WO2020198665A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fibroblast activation protein binding agents and use thereof
|
|
JP7773376B2
(ja)
|
2019-05-15 |
2025-11-19 |
シンセックス, インコーポレイテッド |
タンパク質の選択的分解
|
|
JP7727628B2
(ja)
|
2019-12-03 |
2025-08-21 |
アラマー バイオサイエンシーズ, インク. |
核酸結合免疫サンドイッチアッセイ(nulisa)
|
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
|
GB202009710D0
(en)
*
|
2020-06-25 |
2020-08-12 |
Univ Bath |
Cross-linking methods
|
|
CA3195512A1
(en)
|
2020-10-14 |
2022-04-21 |
Vahe Bedian |
Compositions and methods for treatment of thyroid eye disease
|
|
US12704508B2
(en)
|
2021-06-02 |
2026-08-11 |
Alamar Biosciences, Inc. |
Nucleic acid linked immune-sandwich assay (NULISA)
|
|
JP2024531151A
(ja)
|
2021-08-10 |
2024-08-29 |
ビリジアン セラピューティクス, インコーポレイテッド |
甲状腺眼疾患の処置のための組成物、用量および方法
|
|
US20250304677A1
(en)
|
2022-07-04 |
2025-10-02 |
Vib Vzw |
Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
|
|
AU2023356326A1
(en)
|
2022-10-06 |
2025-03-27 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
CN120282987A
(zh)
|
2022-11-30 |
2025-07-08 |
因特格尔莫来库乐有限公司 |
包括双特异性型式的针对紧密连接蛋白6的抗体
|
|
JP2026519919A
(ja)
|
2023-04-03 |
2026-06-19 |
ブイアイビー ブイゼットダブリュ |
血液脳関門通過抗体
|
|
CN122003247A
(zh)
|
2023-07-07 |
2026-05-08 |
维里迪安治疗公司 |
治疗活动性和慢性甲状腺眼病的方法
|
|
KR20260044219A
(ko)
|
2023-07-21 |
2026-04-01 |
매로우 테라퓨틱스, 인크. |
조혈 세포 표적화 접합체 및 관련 방법
|
|
AU2024373680A1
(en)
|
2023-11-03 |
2026-06-18 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
AU2024408268A1
(en)
|
2023-12-17 |
2026-07-09 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
TW202613158A
(zh)
|
2024-05-16 |
2026-04-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
US20260015407A1
(en)
|
2024-07-15 |
2026-01-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|
|
WO2026122747A2
(en)
|
2024-12-05 |
2026-06-11 |
Flagship Pioneering Innovations Vii, Llc |
Novel immunomodulatory proteins and related methods
|